Nasus Pharma Ltd.
NSRX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$30.23M
Close$
$0.14
95.8% downside
Current Fair Value
95.8% downsideOvervalued by 95.8% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $30.23 Million |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-0.72 |
| Beta | 4.2 |
| Outstanding Shares | 11,070,458 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -3.37 |
|---|---|
| PEG | -0.4 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$-0.27
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
March 3, 2027
EPS Estimate
$-0.73
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Nasus Pharma Ltd.
7 employees
CEO: Brendan O'Grady
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditio...